Pfizer to debut Chantix DTC work this month
Ian Read said the US debut, slated for Sept. 24, “should add to our momentum” for Chantix (varenicline tartrate), which gained marketing clearance last year under an accelerated, six-month review and generated $168 million in revenue during the first six months of 2007.
“We are just in the early stages of tapping into the potential of this product,” said Read, a Pfizer VP and president of its Worldwide Pharma Operations, during the Bank of America Annual Investment Conference today.
McCann HumanCare, tasked with the DTC account, deferred questions to the client. The McCann consumer unit also handles Pfizer's Aricept and Viagra. Euro RSCG Life LM&P handles professional work, while Cadient claims the interactive side.
In a second-quarter earnings statement, the company said nearly 2.5 million
Pfizer added that it has partnered with regulators and independent medical organizations and has supported expanding coverage to uninsured patients.